替格瑞洛与氯吡格雷治疗急性冠脉综合征患者的效果对比  

Comparison of the effects of ticagrelor and clopidogrel in the treatment of patients with acute coronary syndrome

作　　者：陈芬芬 宗春燕 杨娇娇[1] 俞春梅 CHEN Fenfen;ZONG Chunyan;YANG Jiaojiao;YU Chunmei(Emergency Department,Nantong First People's Hospital,Nantong 226001,China)

机构地区：[1]南通市第一人民医院急诊科,江苏南通226001

出　　处：《临床医学研究与实践》2020年第31期83-85,共3页Clinical Research and Practice

摘　　要：目的比较替格瑞洛和氯吡格雷在急性冠脉综合征(ACS)患者经皮冠状动脉介入(PCI)术后治疗中的效果。方法将2017年2月至2019年1月本院收治的PCI术后的146例ACS患者按照治疗方法分为氯吡格雷组和替格瑞洛组,各73例,两组分别给予氯吡格雷和替格瑞洛进行治疗。比较两组治疗前及治疗24 h、7 d、28 d后的血小板凝集率(PAR)、临床疗效与不良事件发生情况。结果治疗24 h、7 d、28 d后,两组PAR均较治疗前显著下降,且替格瑞洛组均显著低于氯吡格雷组(P<0.05),随着时间的变化,替格瑞洛组的下降速度显著高于氯吡格雷组(P<0.05)。替格瑞洛组的治疗总有效率为91.78%,高于氯吡格雷组的79.45%,差异有统计学意义(P<0.05)。氯吡格雷组的MACCE总发生率为17.81%,显著高于替格瑞洛组的2.74%,差异有统计学意义(P<0.05);两组的出血率比较,差异不具有统计学意义(P>0.05)。结论与氯吡格雷相比,替格瑞洛对ACS患者血小板聚集状态改善效果更为显著,且临床疗效显著、安全性较高。Objective To compare the effects of ticagrelor and clopidogrel in the treatment of patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods A total of 146 patients with ACS after PCI admitted in our hospital from February 2017 to January 2019 were divided into clopidogrel group and ticagrelor group by the treatment method,with 73 cases in each group,and the two groups were treated with clopidogrel and ticagrelor respectively.The platelet aggregation rate(PAR)before treatment and after 24 h,7 d and 28 d of treatment,clinical efficacy and occurrence of adverse events were compared between the two groups.Results After 24 h,7 d and 28 d of treatment,PAR in the two groups decreased significantly compared with those before treatment,and those in the ticagrelor group were significantly lower than the clopidogrel group(P<0.05),with the change of time,the decline rate of the ticagrelor group was significantly higher than that of the clopidogrel group(P<0.05).The total effective rate of treatment of the ticagrelor group was 91.78%,which was higher than 79.45%of the clopidogrel group,and the difference was statistically significant(P<0.05).The total incidence of MACCE in the clopidogrel group was 17.81%,which was significantly higher than 2.74%in the ticagrelor group,and the difference was statistically significant(P<0.05);there was no significant difference in bleeding rate between the two groups(P>0.05).Conclusion Compared with clopidogrel,ticagrelor is more effective in improving platelet aggregation state in ACS patients,and has significant clinical efficacy and higher safety.

关 键 词：急性冠脉综合征 替格瑞洛 氯吡格雷 血小板凝集率 

分 类 号：R541.4[医药卫生—心血管疾病]